IMO the only real guide to the potential value of the Company is recent past transactions which have ranged up to US$2.4 billion, by Big Pharma that clearly have a far better understanding of the potential future revenue subject to the particular products gaining FDA approvals.
Based on early results only there is an indication that both the imaging (Propeller) and therapy (SECuRE) potentially could be Best-In-Class with the Cu64/Cu67 radioisotopes.
Therefore AT THIS STAGE IMO the value of just those two products could command a takeover value at or above US$2.4 billion - at or above 3x current price.
BUT that could change if future results don't continue to outperform.
Research/Valuation, page-424
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.09 |
Change
-0.060(1.17%) |
Mkt cap ! $1.586B | |||
| Open | High | Low | Value | Volume |
| $5.25 | $5.25 | $5.00 | $4.160M | 814.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1728 | $5.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.13 | 1728 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |